News
-
-
-
PRESS RELEASE
Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Medicure Inc. reports Q2 2026 financial results, with $7.4M net revenue, focused on ZYPITAMAG® and AGGRASTAT®, undergoing R&D, EBITDA improved. Conference call on August 17, 2026 -
-
-
-
-
-
PRESS RELEASE
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Medicure Inc. reports Q1 2026 financial results: Total net revenue increased, highlighting revenue sources; EBITDA improved; net loss decreased. Key acquisitions and R&D investments noted -